This database contains 1041 studies, archived under the term: "male"
Click here to filter this large number of results.
Clinical stabilisation in neurodegenerative diseases: clinical study in phase II
Introduction: Neurodegenerative disorders, such as Parkinson’s disease (PD), Alzheimer’s disease (AD) and multiple sclerosis (MS), are progressive pathological conditions in which current treatments have not proved to be effective at curbing their progress (clinical stabilisation). Although they have very different clinical characteristics, they share the same pathophysiological mechanisms of progression. We developed a compound designed […]
The effect of therapeutic touch on behavioral symptoms and cortisol in persons with dementia
Background: Between 75-90% of nursing home (NH) residents with dementia develop behavioral symptoms (BSD) which may be associated with a stress response. Therapeutic touch has been shown to decrease restlessness in NH residents, however the mechanism is unknown. The purpose of this randomized controlled trial (RCT) was to examine the effect of therapeutic touch on […]
Efficacy of acatinol memantine in mild cognitive disorder
An open 6 month clinical trial of efficacy of acatinol has been carried out in patients with mild cognitive disorder (MCD). Forty patients received acatinol and 20 patients of comparison group were treated with piracetam. Mean age of patients was 67,7+/-7,2 years. Patient’s state was assessed with a battery of scales, questionnaires and neuropsychological tests. […]
The effect of videophone communication (with skype and webcam)for elderly patients with dementia and their caregivers
Hori, Miyako,
Kubota, Masakazu,
Ando, Koichi,
Kihara, Takeshi,
Takahashi, Ryosuke,
Kinoshita, Ayae
We conducted an intervention study to clarify how effectively videophone (Skype) was used in the communication for elderly patients with dementia cared at home and their caregivers. For a period of 12 weeks, a patient-caregiver pair(n = 6) communicated with a nurse via computer for 30 minutes once a week. The patient and the caregiver […]
Galantamine (reminyl) in the treatment of severe Alzheimer’s disease
Twenty-five patients with Alzheimer’s disease (AD) in moderate-severe and severe stages received galantamine in dosage 8 mg daily during the 1st month with the following increasing to 16 mg daily. Six patients received 24 mg per day from the 3rd month. The total duration of therapy was 26 weeks. 15 patients received in addition the […]